Key result
NMR metabolomics signature predicts incident CVD in type 2 diabetes with an AUC of ~0.76.
Why the study?
Does an untargeted 1H NMR metabolomics signature predict incident cardiovascular disease in people with type 2 diabetes beyond traditional risk factors?
Case-Control (n=48)
Does an untargeted 1H NMR metabolomics signature predict incident cardiovascular disease in people with type 2 diabetes beyond traditional risk factors?
Answers are grounded in this paper and cite their sources.
Untargeted 1H NMR metabolomics identified a 16-feature signature that predicts cardiovascular risk in people with type 2 diabetes beyond traditional risk factors like LDL cholesterol.
People with type 2 diabetes mellitus (T2DM) are at high risk of cardiovascular disease (CVD), which is often not explained by traditional risk factors such as low-density lipoprotein (LDL) cholesterol. Proton nuclear magnetic resonance (1H NMR) metabolomics is a promising tool to help explain this residual risk. This study aimed to evaluate the incidence of CVD in people with T2DM via untargeted 1H NMR data. The 1H NMR raw spectra of 24 cases and 24 controls (with basal T2DM and with/without CVD at follow-up) matched by age, sex, body mass index, and LDL cholesterol from the Di@bet.es cohort were processed, and the peak-picked features (p = 269) were used in a partial least-squares discriminant analysis classification with repeated double cross-validation and validated against permuted data sets (AUC = 0.758; p-value = 0.011). For each feature, a stringent variable selection method analyzing the distributions of variable importance in projection scores and beta coefficients across all the repeated models was used, yielding a metabolomic signature composed of 16 selected features related to inflammation, triglycerides, muscular function, and HDL particles, together with features putatively arising from albumin, although further validation of the annotations is needed. In summary, untargeted 1H NMR metabolomics can help assess cardiovascular risk in people with T2DM beyond LDL cholesterol.
No takes yet. Share an insight, caveat, or question.
Rehues et al. (2025) conducted a case-control in Type 2 diabetes mellitus (n=48). 1H-NMR-based spectral metabolomics signature vs. Controls without CVD was evaluated on Incidence of CVD (AUC 0.758, p=0.011). A 1H-NMR-based spectral metabolomics signature predicted incident cardiovascular disease in people with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: